{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:35:51Z","timestamp":1783971351687,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T00:00:00Z","timestamp":1454112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients undergoing allogeneic hematopoietic stem cell transplantation (allo\u2010<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>) are at risk of numerous opportunistic infections. <jats:italic>Pneumocystis jirovecii<\/jats:italic> pneumonia (<jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content>) is a potentially life\u2010threatening infection that can develop in immunocompromised individuals. Current prophylaxis for <jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content> includes trimethoprim\u2010sulfamethoxazole (<jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMX<\/jats:styled-content>), dapsone, atovaquone, or inhaled pentamidine (<jats:styled-content style=\"fixed-case\">PEN<\/jats:styled-content>), often with varying breakthrough rates. The use of intravenous (<jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content>) <jats:styled-content style=\"fixed-case\">PEN<\/jats:styled-content> for <jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content> prophylaxis has been evaluated in pediatric patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single\u2010institution retrospective review of electronic medical records was conducted for patients who underwent allo\u2010<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> between January 2001 and May 2013 and who had received at least 1 dose of <jats:styled-content style=\"fixed-case\">IV PEN<\/jats:styled-content> for <jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content> prophylaxis. Data collected included patient demographics, diagnosis, previous chemotherapy, pre\u2010transplant conditioning regimen, other medications, microbiology test results, and clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 113 patients were included in the study. The median number of <jats:styled-content style=\"fixed-case\">PEN<\/jats:styled-content> doses administered per patient was 3 (range 1\u201323). <jats:styled-content style=\"fixed-case\">IV PEN<\/jats:styled-content> was primary <jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content> prophylaxis in 74 of the patients (65%) and second\u2010line prophylaxis in 39 (35%) post transplant, with the majority switching from oral <jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMX<\/jats:styled-content>. Side effects of <jats:styled-content style=\"fixed-case\">IV PEN<\/jats:styled-content> administration were minimal. No patients who received <jats:styled-content style=\"fixed-case\">IV PEN<\/jats:styled-content> prophylaxis developed <jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content> infection. No case of <jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content> was seen in patients who received other agents for <jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content> prophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This retrospective study showed that <jats:styled-content style=\"fixed-case\">IV PEN<\/jats:styled-content> is very effective and well\u2010tolerated prophylaxis for <jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content>;<jats:styled-content style=\"fixed-case\"> IV PEN<\/jats:styled-content> can be considered a favorable alternative for <jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content> in\u00a0situations where other agents might be contraindicated. Our findings provide strong support for prospective studies of <jats:styled-content style=\"fixed-case\">IV PEN<\/jats:styled-content> for <jats:styled-content style=\"fixed-case\">PJP<\/jats:styled-content> prophylaxis in adult <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> recipients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12486","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T21:24:51Z","timestamp":1448486691000},"page":"63-69","source":"Crossref","is-referenced-by-count":15,"title":["Retrospective review of intravenous pentamidine for <i><scp>P<\/scp>neumocystis<\/i> pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1111","volume":"18","author":[{"given":"R.","family":"Diri","sequence":"first","affiliation":[{"name":"The University of Arizona College of Pharmacy Tucson Arizona USA"},{"name":"College of Pharmacy King Abdulaziz University Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Anwer","sequence":"additional","affiliation":[{"name":"Medicine Department The University of Arizona College of Medicine Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Yeager","sequence":"additional","affiliation":[{"name":"Medicine Department The University of Arizona College of Medicine Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Krishnadasan","sequence":"additional","affiliation":[{"name":"Medicine Department The University of Arizona College of Medicine Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"McBride","sequence":"additional","affiliation":[{"name":"Pharmacy Department The University of Arizona Cancer Center Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,30]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032588"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/339548"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430110015002"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705149"},{"issue":"3","key":"e_1_2_5_6_1","first-page":"267","article-title":"Pneumocystis carinii pneumonitis following bone marrow transplantation","volume":"10","author":"Tuan I","year":"1992","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"e_1_2_5_7_1","first-page":"1057","article-title":"Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation","volume":"17","author":"Lyytikainen O","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.4065\/82.9.1052"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-1360"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2002.t01-1-00008.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503163321101"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70050-4"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.4.770-782.2004"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.995"},{"issue":"1","key":"e_1_2_5_16_1","first-page":"39","article-title":"Risk factors and prevention of Pneumocystis carinii pneumonia after bone marrow transplantation","volume":"87","author":"Link H","year":"1992","journal-title":"Med Klin (Munich)"},{"key":"e_1_2_5_17_1","unstructured":"DykewiczC KaplanJ.Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients 2001. Available at:http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr4910a1.htm(Accessed 10\/20\/2014)."},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318292f560"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21287"},{"issue":"2","key":"e_1_2_5_20_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.1994.12.2.258","article-title":"Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim\/sulfamethoxazole","volume":"12","author":"Mustafa M","year":"1994","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-006-0149-4"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/313509"},{"key":"e_1_2_5_23_1","unstructured":"ThomasC LimperA.Treatment and prevention of Pneumocystis pneumonia in non\u2010HIV\u2010infected patients 2013. Available at:http:\/\/www.uptodate.com.ezproxy1.library.arizona.edu\/contents\/treatment-and-prevention-of-Pneumocystis-pneumonia-in-nonhiv-infected-patients?source=search_result&search=pcp+prophylaxis&selectedTitle=1%7E45(Accessed 10\/12\/2014)."},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21774"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812243392604"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/314893"},{"key":"e_1_2_5_27_1","unstructured":"Centers for Disease Control and Prevention.Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus 2001. Available at:http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/00016444.htm(Accessed 11\/24\/2014)."},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01648579"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/1043454211408101"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198705000-00010"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000044"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2011.01399.x"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12486","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:50:13Z","timestamp":1695541813000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,30]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/tid.12486"],"URL":"https:\/\/doi.org\/10.1111\/tid.12486","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,30]]}}}